Physician profile
James E Davidson
NPI 1669965133
$7,607.92
in general payments reported to CMS, 2019-2025
49 companies · $4,061 in 2025
The $4,061 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.32 · 2022: $486 · 2023: $1,358 · 2024: $1,650 · 2025: $4,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,658 · Travel and Lodging: $1,770 · Education: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,657.75 |
| Travel and Lodging | $1,770.10 |
| Education | $640.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,591.99 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $511.09 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Novartis Pharmaceuticals Corporation | $488.47 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $472.00 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $289.29 | 2023-2025 | Padcev, Cresemba, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $241.16 | 2021-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $206.17 | 2022-2025 | Polivy, Venclexta, Phesgo |
| Celgene Corporation | $199.50 | 2023-2025 | Reblozyl, Breyanzi, Pomalyst |
| Seagen INC. | $197.62 | 2023 | Tukysa, Padcev |
| Janssen Biotech, INC. | $195.57 | 2022-2025 | Tecvayli, Erleada, Rybrevant |
| Pfizer INC. | $175.36 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.25 | 2023-2025 | Ninlaro, Alunbrig, Iclusig |
| Astrazeneca Pharmaceuticals Lp | $167.69 | 2023-2025 | Calquence, Tagrisso |
| Abbvie INC. | $159.53 | 2021-2025 | |
| Amgen INC. | $119.41 | 2022-2023 | Xgeva, Nplate, Vectibix |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.